macrocyclic peptideTherapeutic Peptides
Zilucoplan (Zilbrysq)
A complement C5 inhibitor approved for generalized myasthenia gravis. A macrocyclic peptide that prevents complement-mediated destruction of the neuromuscular junction. Administered as subcutaneous self-injection.
complement-inhibitionmyasthenia-gravisautoimmuneFDA-approved
3D Structure
3D Structure
3562.2 Da
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
ESI-MS (computed)
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity dataLab Reports
0 reports on file
Summary
A complement C5 inhibitor approved for generalized myasthenia gravis. A macrocyclic peptide that prevents complement-mediated destruction of the neuromuscular junction. Administered as subcutaneous se…